Wei Xie, M.D., Ph.D.

  • Assistant Professor of Pathology & Laboratory Medicine, School of Medicine


After completing medical school in China, Dr. Xie received her Ph.D. in cardiovascular pathophysiology from Texas A&M University. She continued her residency training at Baylor College of Medicine, and completed her fellowships in Hematopathology at MD Anderson Cancer Center, and Molecular Genetic Pathology at Baylor College of Medicine, respectively. Her role includes diagnosis of hematopoietic disorders, and interpretation of molecular tests such as next-generation sequencing (NGS). Her research interests include molecular mechanisms of lymphoid and myeloid neoplasms and microenvironment, clonal hematopoiesis detected by NGS, and translation of the findings into patient care.

Dr. Xie comes to Portland with her husband and two kids. In her spare time, she enjoys cooking, reading, watching movies and traveling with her family.


  • M.D., 2003, Hunan University of Chinese Medicine
  • Ph.D., 2011, Texas A&M University Health Science Center
  • Residency:

    • Anatomic and Clinical Pathology Residency, Baylor College of Medicine, Houston, Texas, 2013-2017
    • Associate chief, 2015-2016
  • Fellowship:

    • Molecular Genetic Pathology Fellowship, Baylor College of Medicine, Houston, TX, 2019-2020
    • Chief Fellow, Hematopathology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017-2019
  • Certifications:

    • Molecular Genetic Pathology (American Board of Pathology), 2020
    • Hematopathology (American Board of Pathology), 2018
    • Anatomic and Clinical Pathology (American Board of Pathology), 2017


Elsevier pure profile

Selected publications

  • Xie W, Medeiros LJ, Li S, Yin CC, Xu J et al. PD-1/PD-L1 Pathway and its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large Cell Lymphomas. Curr Hematol Malig Rep. 2020 May 11. PMID: 32394185
  • Xie W, Xu J, Hu S, Li S, Wang W, Yin CC et al. iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53mutation and dismal outcome. Mod Pathol. 2020 Feb 7. (Journal Cover in July 2020) PMID: 32034282
  • Xie W,   Tang G, Wang E, Kim Y, Cloe A, Shen Q et al. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic neoplasms: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Jan 31. PMID: 32006151
  • Xie W, Wang SA, Yin CC, Xu J, Li S, Bueso-Ramos CE, et al. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes. Exp Mol Pathol. 2019; 108:131-6. PMID: 31004601
  • Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults. Ann Hematol. 2019 May;98(5):1149-1157. PMID: 30759270
  • Xie W, Chen Z, Wang SA, Hu S, Li S, Miranda RN, et al. Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leuk Lymphoma. 2019:1-9.  PMID:31017498
  • Xie W, Xu J. Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia. Blood. 2019;133(2):182. PMID:30630849


  • {{ pub.journalAssociation.journal.name.text[0].value }}